Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 11, 2010 - Issue 6
Submit an article Journal homepage
370
Views
7
CrossRef citations to date
0
Altmetric
Clinical Trial Evaluation

Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial)

Evaluation of ‘Dabigatran versus Warfarin in the treatment of acute venous thromboembolism'. N Engl J Med 2009;361:2342-52

Paolo Prandoni University of Padua, Department of Cardiothoracic and Vascular Sciences, Thromboembolism Unit, Via Giustiniani 2, 35128 Padua, Italy +39 049 8212656; +39 049 8218731; [email protected]
, MD PhD &
Ali Taher American University of Beirut Medical Center, Department of Internal Medicine, Beirut, Lebanon
, MD
Pages 1035-1037 | Published online: 22 Mar 2010

Bibliography

  • Schulman S, Kearon C, Kakkar AK, Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
  • Ansell J, Hirsh J, Hylek E, Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133:160-98S
  • Sanford M, Plosker GL. Dabigatran etexilate. Drugs 2008;68:1699-709
  • Eriksson BI, Dahl OE, Rosencher N, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56
  • Eriksson BI, Dahl OE, Rosencher N, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85
  • Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
  • Gage BF, Eby C, Johnson JA, Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84:326-31
  • Fiessinger JN, Huisman MV, Davidson BL, Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-9
  • Schulman S, Wahlander K, Lundstrom T, Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.